Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

Basmisanil Positron Emission Tomography Study in Japanese Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Basmisanil

First Posted Date: 2015-08-27

Last Posted Date: 2017-01-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 6

Registration Number: NCT02534207

Locations: 🇬🇧
Hammersmith Medicines Research; Central Middlesex Hospital, London, United Kingdom
🇬🇧
Imanova Limited, London, United Kingdom

A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)

Phase 2

Completed

Conditions: Lymphocytic Leukemia, Chronic

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Rituximab

First Posted Date: 2015-08-26

Last Posted Date: 2016-05-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 34

Registration Number: NCT02533401

A Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate

Completed

Conditions: Metastatic Breast Cancer

First Posted Date: 2015-08-19

Last Posted Date: 2015-08-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 582

Registration Number: NCT02528747

A Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Pirfenidone

First Posted Date: 2015-08-17

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 44

Registration Number: NCT02525484

A Multiple Ascending-Dose Study of RG7625 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Placebo
Drug: RG7625

First Posted Date: 2015-08-13

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 33

Registration Number: NCT02521610

Study of an Investigational Drug, RO7239361 (BMS-986089), in Ambulatory Boys With DMD

Phase 1

Terminated

Conditions: Muscular Dystrophy (DMD)

Interventions: Drug: RO7239361
Drug: Placebo

First Posted Date: 2015-08-05

Last Posted Date: 2020-11-04

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 43

Registration Number: NCT02515669

Locations: 🇺🇸
Kennedy Krieger Institute, Baltimore, Maryland, United States
🇨🇦
Children'S Hospital of Eastern Ontario, Ottawa, Ontario, Canada
🇺🇸
Saint Louis Children's Hospital, Saint Louis, Missouri, United States

and more 9 locations

An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria

Completed

Conditions: Hepatitis C

Interventions: Drug: Peginterferon alfa-2a
Drug: Ribavirin

First Posted Date: 2015-08-04

Last Posted Date: 2017-04-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 463

Registration Number: NCT02515279

Locations: 🇦🇹
A.Ö. Krankenhaus Der Barmherzigen Schwestern Ried; Interne Abtl., Ried-innkreis, Austria

A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Atezolizumab
Drug: Azacitidine

First Posted Date: 2015-07-27

Last Posted Date: 2019-08-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 46

Registration Number: NCT02508870

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
City of Hope, Duarte, California, United States

and more 12 locations

An Observational Quality of Life Study in Participants With Rheumatoid Arthritis Treated With Rituximab

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2015-07-24

Last Posted Date: 2016-02-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 94

Registration Number: NCT02507752

Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin

Completed

Conditions: Chronic Hepatitis C

First Posted Date: 2015-07-24

Last Posted Date: 2017-11-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 10

Registration Number: NCT02508090

Locations: 🇵🇷
Fundacion de Investigacion de Diego, San Juan, Puerto Rico

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy